Prostate Cancer Patients Report on Benefits of Proton Therapy

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Prostate Cancer Patients Report on Benefits of Proton Therapy"

Transcription

1 Prostate Cancer Patients Report on Benefits of Proton Therapy Dobson DaVanzo & Associates, LLC Vienna, VA

2 Prostate Cancer Patients Report on Benefits of Proton Therapy Submitted to: National Association for Proton Therapy (NAPT) Submitted by: Joan E. DaVanzo, Ph.D., M.S.W. Kevin Reuter Anne Pick, M.P.H. Tuesday, February 12, 2013 Final Report

3 Table of Contents Introduction... 4 Background... 4 Methods... 5 Key Findings... 5 Detailed Study Findings... 7 Respondent Demographics... 7 EPIC Findings... 9 Satisfaction with Proton Therapy Discussion PROSTATE CANCER PATIENTS REPORT ON BENEFITS OF PROTON THERAPY

4 Introduction The National Association for Proton Therapy (NAPT) commissioned Dobson DaVanzo & Associates, LLC (Dobson DaVanzo) to investigate outcomes and patient satisfaction associated with the use of proton therapy in treating prostate cancer. Background Close to 2,000 patients who were treated for prostate cancer with proton therapy from 1991 to 2010 completed a survey distributed by the Brotherhood of the Balloon (BoB), which examined satisfaction with care, quality of life, emotional and physical health limitations, urinary function, sexual function, bladder function, and bowel function. These 2,000 patients represent approximately 20 percent of all patients who had received proton therapy for prostate cancer prior to The BoB survey incorporated the Expanded Prostate Cancer Index Composite (EPIC), a validated instrument developed by the University of Michigan and UCLA that measures health related quality of life (HRQOL), specifically among men with prostate cancer. EPIC assesses a patient s Health Related Quality of Life (HRQOL) in urinary, sexual, bowel, and hormonal domains. In addition, EPIC derives subscales for each category, which examine function (measure habits associated with the category) and bother (degree of annoyance associated with symptoms related to the category) for each HRQOL category. Urinary scores also contain subcategories related to incontinence (measures loss of bladder control) and irritation/obstruction (measures pain or bleeding associated with urination). The BoB survey also incorporated the American Urological Association (AUA) symptom index, which provides a clinical context for urinary measures (a higher score indicating more severe symptoms), and a Medical Outcomes Study SF-12 score which is a patient s report of physical and mental health status (a higher score indicating better HRQOL) 1. Additionally, items were included to examine patient demographics, 1 THE SF-12 is a validated measure of General Health Function developed by RAND. It examines physical and mental HRQOL, and provides both a physical and mental HRQOL score. PROSTATE CANCER PATIENTS REPORT ON BENEFITS OF PROTON THERAPY FINAL REPORT

5 self-rated health status, clinical characteristics, type of treatment received, and reported problems prior to treatment. Methods Our first step was to tabulate all of the survey responses and calculate descriptive statistics to describe the following characteristics of the sample: age distribution, selfrated health status, types of treatment received, whether the cancer was in remission, pretreatment PSA, pre-treatment Gleason Score, pre-treatment T-Stage, and whether respondent was experiencing any problems with bowel, bladder, or sexual functioning prior to treatment. Our next step was to calculate EPIC scores based on each patients reported post-treatment condition. EPIC Summary Scores were calculated using scoring instructions provided by the University of Michigan and UCLA. Responses for each item in the survey form a Likert scale, transformed linearly to a scale. For each item, a higher score represents a better Health Related Quality of Life (HRQOL). Multi-item summary scores were then created for urinary, bowel, sexual, and hormonal symptoms by averaging items within a response category corresponding to these symptoms. Subscale scores were also calculated for these symptoms, which included function (item measures habits associated with the category) and bother (item measures degree of annoyance associated with symptoms related to the category). Urinary scores also contain subcategories related to incontinence (item that measures loss of bladder control) and irritation/obstruction (items that measure pain or bleeding associated with urination). An AUA symptom index, and Medical Outcomes Study SF-12 score was also calculated for each patient. These measures were then cross-tabulated by treatment modality (whether the patient received proton therapy only or proton plus another type of therapy: hormone or photon therapy), by time elapsed since treatment, and by whether the patient had reported problems associated with sexual, urinary, or bowel function prior to treatment. Individual items relating to satisfaction with proton therapy, quality of life, level of pain, and physical and emotional functioning were also cross tabulated with time since completing proton therapy and treatment modality. Differences were tested using Chi-square and t-tests. Key Findings Approximately 99 percent of respondents stated that they believed they made the best treatment decision for themselves, and 98 percent reported that they had recommended proton therapy to others (Exhibit 15). Approximately 96 percent of patients were satisfied or extremely satisfied with proton therapy (Exhibit 19). PROSTATE CANCER PATIENTS REPORT ON BENEFITS OF PROTON THERAPY FINAL REPORT

6 Ninety-one percent of patients reported that their quality of life was better or the same today than it was before their treatment, and only 9 percent reported that their quality of life was worse (Exhibit 21). Ninety-three percent of respondents reported that physical health or emotional problems did not interfere, or interfered very little, with their social activities (Exhibit 23). Those who completed proton therapy for the treatment of prostate cancer had similar urinary, bowel, and hormonal HRQOL scores as healthy individuals. Proton therapy patients did have lower sexual HRQOL scores than healthy individuals; however this finding was mostly associated with those patients who received hormone therapy in addition to proton therapy. When looking at patients who received only proton therapy for the treatment of prostate cancer (did not receive hormone or photon therapy), proton therapy patients reported equivalent HRQOL to healthy individuals, except for one HRQOL category ( Sexual Bother 2 ) (Exhibit 3). Respondents who were treated with photon therapy in addition to proton therapy had lower bowel, sexual, and hormonal HRQOL scores than proton only respondents (Exhibit 4a). Those who received hormone therapy in addition to proton therapy had lower sexual and hormonal HRQOL scores than proton only respondents. Those receiving photon or hormone therapy in addition to proton therapy also reported lower SF-12 Physical Component Score (PCS) scores compared to those only receiving proton therapy, indicating a lower physical HRQOL (Exhibit 4b). 2 Patients rating of the level of annoyance associated with their sexual symptoms PROSTATE CANCER PATIENTS REPORT ON BENEFITS OF PROTON THERAPY FINAL REPORT

7 Respondent Demographics More than half of respondents (52.5%) completed the BoB survey at least 3 years following the completion of their treatment (Exhibit 1). All survey respondents received proton therapy (n=1862), 16 percent of respondents also received hormone therapy, and 10 percent received photon therapy (Exhibit 2). Additionally, most respondents (96.9 percent) had not received any other treatment prior to their proton therapy. The majority of respondents received proton therapy between ages 61 and 70 with over one-quarter (28.1 percent) receiving proton therapy between ages 66 and 70. Prior to treatment, over one-quarter of patients (27.3 percent) reported problems with urinary function, and 23.8 percent reported problems with sexual function. Overall, less than four percent of respondents reported Fair or Poor health following proton therapy, while 78 percent reported Very Good or Excellent health. PROSTATE CANCER PATIENTS REPORT ON BENEFITS OF PROTON THERAPY FINAL REPORT

8 Number of Respondents Detailed Study Findings Exhibit 1. Respondent s Time Elapsed since the Completion of Proton Therapy to Completing the Survey years 1 years 2 years 3 years 4 years 5 years 6 or more years Years Since Treatment Exhibit 2: Characteristics of Sample Variable Results Age Distribution (n=1862) % 22.4% 28.1% 15.2% 6.1% Self Rated Health Status (n=1860) Excellent Very Good Good Fair Poor Problems Experienced Prior to Treatment (n=798) 34.0% 44.3% 18.3% 3.1% 0.3% Sexual Urinary Bowel Other 23.8% 27.3% 1.8% 0.8% Treatment Received Prior to Proton (n=109) Surgery Cyro HIFU Other Type of Treatment Received (n=1862) Proton Photon Hormones 100.0% 10.0% 16.2% Pre-treatment T-Stage (n=1026) T1 T2 T Cancer in Remission (n=1760) Yes No 95.1% 4.9% Pre-treatment PSA (n=1750) Mean Median Standard Dev Pre-treatment Gleason Score (n=1586) Mean Median Standard Dev PROSTATE CANCER PATIENTS REPORT ON BENEFITS OF PROTON THERAPY FINAL REPORT

9 EPIC Findings EPIC Scores were compared for the following three subgroups of patients: 1) respondents who received proton therapy for the treatment of prostate cancer; 2) respondents who received only proton therapy for the treatment of prostate cancer (excludes patients also receiving hormone or photon therapy); 3) respondents who did not have prostate cancer. We found no differences in urinary or bowel summary or subscale scores across the three groups (Exhibit 3). Sexual summary scores, and sexual bother and function sub-scores however, were lower for those who had received proton therapy (indicating a lower HRQOL) than for the healthy control group (p<0.05). When comparing those who received only proton therapy for the treatment of their prostate cancer (excluding those who also received photon or hormone therapy), proton only therapy patients had a significantly lower HRQOL in only the Sexual Bother category than the healthy group (p<0.05), but higher than those who received either hormone or photon therapy. Exhibits 4a and 4b show a comparison across groups who had prostate cancer: 1) patients who received only proton therapy; 2) patients who received proton therapy plus photon therapy, and; 3) patients who received hormone therapy in addition to proton therapy. Exhibit 4a shows summary EPIC scores, Exhibit 4b shows the sub-scores. We found greater variation in EPIC scores across these groups (some of this variation is related to unequal group sizes). However, those patients who had received only proton therapy had the highest EPIC scores on 13 of the 18 sub-score measures. The proton only patients had the highest EPIC scores for Sexual Summary, Sexual Function, and Sexual Bother (p<0.05), as well as Hormonal Summary, Hormonal Function, and Hormonal Bother (p<0.05). Those also being treated with hormone therapy had a sexual summary score of 39.9 and those also being treated with photon therapy had a sexual summary score of These scores are lower than the Sexual Summary score of those receiving only proton therapy for their treatment (57.8) (p<0.05). Respondents who received photon therapy had lower bowel and hormonal scores (p<0.05), while those receiving hormone therapy had lower hormonal scores compared to proton only patients (p<0.05). Exhibit 5 shows that the length of time a patient has been receiving hormone therapy is also associated with lower sexual HRQOL. In particular, those on hormone therapy for greater than 24 months had an average EPIC sexual function score of just 26.2 (vs for those on hormone therapy for less than 24 months) (p<0.05). Overall, however, length of hormone therapy was not associated with major differences between the groups (due to small sample sizes). PROSTATE CANCER PATIENTS REPORT ON BENEFITS OF PROTON THERAPY FINAL REPORT

10 Exhibit 3. EPIC Scores of Patients Who Have Underwent Proton Therapy for Treatment of Prostate Cancer Compared to EPIC Scores of Patients Who Have Not Been Diagnosed with Prostate Cancer. Patients w/ Prostate Cancer who Had Proton Therapy (n=1961) Patients w/ Prostate Cancer who only Had Proton Therapy (n=1487) Patients w/o Prostate Cancer (n=112) Urinary Summary Urinary Function Urinary Bother Urinary Irritative Urinary Incontinence Bowel Summary Bowel Function Bowel Bother Sexual Summary 53.7* Sexual Function 49.5* Sexual Bother 63.1* 66.7* 74.3 Hormonal Summary Hormonal Function Hormonal Bother * 92.8 Satisfaction AUA Symptom Score SF-12 PCS SF-12 MCS *p<0.05. Note: SF-12 PCS= Physical Component Score, a selfrated physical health status. SF-12 MCS= Mental Component Score, a self-rated mental health status. Exhibit 4a. EPIC Scores of Patients Who Have Underwent Proton Therapy for Treatment of Prostate Cancer by Treatment Modality (Summary Scores) Just Proton (n=1487) Proton and Photon (n=186) Proton and Hormone (n=302) Urinary Summary Bowel Summary * 91.3 Sexual Summary 57.8* 35.9* 39.9* Hormonal Summary 93.3* 88.4* 87.7*. *p<0.05 PROSTATE CANCER PATIENTS REPORT ON BENEFITS OF PROTON THERAPY FINAL REPORT

11 Exhibit 4b. EPIC Scores of Patients Who Have Underwent Proton Therapy for Treatment of Prostate Cancer by Treatment Modality Just Proton (n=1487) Proton and Photon (n=186) Proton and Hormone (n=302) Urinary Summary Urinary Function Urinary Bother Urinary Irritative Urinary Incontinence Bowel Summary * 91.3 Bowel Function * 91.7 Bowel Bother * 90.8 Sexual Summary 57.8* 35.9* 39.9* Sexual Function 53.7* 30.8* 35.5* Sexual Bother 66.7* 47.3* 50.2* Hormonal Summary 93.3* 88.4* 87.7* Hormonal Function 91.4* 86.1* 84.9* Hormonal Bother 94.9* 90.3* 90.0* Satisfaction * 93.2 AUA Symptom Score SF-12 PCS * 50.3* SF-12 MCS *p<0.05 PROSTATE CANCER PATIENTS REPORT ON BENEFITS OF PROTON THERAPY FINAL REPORT

12 Exhibit 5. EPIC Scores of Patients Who Were Treated with Hormone Therapy in Addition to Proton Therapy by Months Treated with Hormone Therapy <24 months Hormone Therapy (n=247) 24 months Hormone Therapy (n=55) Urinary Summary Urinary Function Urinary Bother Urinary Irritative Urinary Incontinence Bowel Summary Bowel Function Bowel Bother Sexual Summary Sexual Function * Sexual Bother Hormonal Summary Hormonal Function Hormonal Bother Satisfaction AUA Symptom Score SF-12 PCS SF-12 MCS *p<0.05 As shown in Exhibit 6, those who received only proton therapy had the lowest percentage of total reported functional problems prior to treatment, relative to the groups who received combined treatment. When comparing respondents who reported problems with sexual, urinary, or bowel function prior to treatment, those who received hormone therapy in addition to proton therapy had a lower hormonal and sexual HRQOL, while those who also received photon therapy reported a lower sexual HRQOL (p<0.05) and a lower Hormone Bother score (p<0.05) compared to respondents receiving only proton therapy (Exhibit 7). PROSTATE CANCER PATIENTS REPORT ON BENEFITS OF PROTON THERAPY FINAL REPORT

13 Exhibit 6. Proportion of Patients Reporting Problems with Sexual Function, Urinary Function, Bowel Function or Other Problems Prior to Treatment by Treatment Modality Sexual Function Urinary Function Bowel Function Other Problems Total Treatment Modality n % n % n % n % n % Only Receiving Proton Therapy (n=1487) % % % % % Receiving Proton and Photon Therapy (n=186) % % 4 2.2% 1 0.5% % Receiving Proton and Hormone Therapy (n=302) % % 3 1.0% 1 0.3% %. Exhibit 7. EPIC Scores Post-Treatment of Patients Reporting Problems with Sexual, Urinary, Bowel, or Other Function Prior to Treatment by Treatment Modality Proton Therapy Only (n=601) Proton and Photon Therapy (n=78) Proton and Hormone Therapy (n=160) All Treatment Modalities (n=779) Urinary Summary Urinary Function Urinary Bother Urinary Irritative Urinary Incontinence Bowel Summary Bowel Function Bowel Bother Sexual Summary 47.6* 27.4* 34.5* 44.3 Sexual Function 43.9* 22.8* 31.1* 40.7 Sexual Bother 55.9* 38.4* 43.3* 52.8 Hormonal Summary 91.9* * 90.9 Hormonal Function 89.8* * 88.7 Hormonal Bother 93.8* 89.3* 88.8* 92.7 Satisfaction AUA Symptom Score SF-12 PCS SF-12 MCS *p <0.05 Although respondents who received only proton therapy reported lower sexual problems prior to treatment, Exhibit 8 shows that of those who did report sexual problems prior to treatment, patients who received only proton therapy had the highest sexual EPIC scores post-treatment compared to those who received other treatment modalities in addition to proton therapy (p<0.05). Exhibit 9 and 10, show that of those who reported problems PROSTATE CANCER PATIENTS REPORT ON BENEFITS OF PROTON THERAPY FINAL REPORT

14 with urinary and bowel function prior to treatment, respectively, treatment modality did not have a substantial effect on post-treatment EPIC scores. Exhibit 8. EPIC Summary Scores Post-Treatment of Patients Reporting Problems with Sexual Function Prior to Treatment by Treatment Modality Proton Therapy Only (n=326) Photon and Proton Therapy (n=53) Hormone and Proton Therapy (n=96) All Treatment Modalities (n=441) Sexual Summary 36.7* 25.8* 26.3* 34.2 Sexual Function 33.6* 20.8* 22.2* 30.8 Sexual Bother 43.5* 36.9* 35.9* *p<0.05 Exhibit 9. EPIC Summary Scores Post-Treatment of Patients Reporting Problems with Urinary Function Prior to Treatment by Treatment Modality Proton Therapy Only (n=390) Proton and Photon Therapy (n=45) Hormone and Proton Therapy (n=105) All Treatment Modalities (n=503) Urinary Summary Urinary Function Urinary Bother Urinary Irritative Urinary Incontinence Exhibit 10. EPIC Summary Scores Post-Treatment of Patients Reporting Problems with Bowel Function Prior to Treatment by Treatment Modality Proton Therapy Only (n=29) Photon and Proton Therapy (n=4) Hormone and Proton Therapy (n=3) All Treatment Modalities (n=26) Bowel Summary Bowel Function Bowel Bother In comparison, Exhibit 11 shows EPIC scores by treatment modality of respondents that did not report problems prior to treatment. Patients receiving only proton therapy who did not report problems prior to treatment had higher HRQOL scores in several areas, compared to those also receiving other treatments (p<0.05). Proton only patients scored higher in all sexual and hormone categories compared to respondents receiving photon therapy and those receiving hormone therapy (p<0.05) among these patients. PROSTATE CANCER PATIENTS REPORT ON BENEFITS OF PROTON THERAPY FINAL REPORT

15 Exhibit 11. EPIC Summary Scores Post-Treatment of Patients Not Reporting Problems with Sexual, Urinary, Bowel, or Other Function Prior to Treatment by Treatment Modality Proton Therapy Only (n=898) Proton and Photon Therapy (n=103) Proton and Hormone Therapy (n=142) All Treatment Modalities (n=1092) Urinary Summary Urinary Function Urinary Bother Urinary Irritative Urinary Incontinence Bowel Summary Bowel Function * Bowel Bother Sexual Summary 64.4* 42.7* 46.2* 61.3 Sexual Function 60.0* 36.9* 40.5* 56.7 Sexual Bother 74.0* 54.1* 58.2* 71.3 Hormonal Summary 94.2* 88.5* 88.7* 93.3 Hormonal Function 92.5* 85.6* 85.5* 91.4 Hormonal Bother 95.6* 91.0* 91.4* 94.9 Satisfaction AUA Symptom Score SF-12 PCS SF-12 MCS *p <0.05 Exhibit 12a and 12b show EPIC scores by length of time since treatment. Overall, length of time since the completion of treatment did not play a significant role in respondents HRQOL, except those who had just completed proton therapy (0 years since treatment) had lower urinary (summary, bother and irritative) HRQOL scores (p<0.05). AUA symptom scores (indicating worse urinary symptoms) were higher (symptoms were worse) for this group (p<0.05), showing that a lower urinary HRQOL was associated with worse urinary symptoms. Respondents completing the survey one year following treatment had higher sexual function and sexual bother HRQOL scores (p<0.05), while those six or more years following the completion of proton therapy had lower sexual HRQOL scores (p<0.05), urinary incontinence scores (p<0.05), and SF-12 PCS scores (indicating a lower physical HRQOL) (p<0.05). These differences, however, are largely thought to be associated with increased age as opposed to effects of the cancer therapy. PROSTATE CANCER PATIENTS REPORT ON BENEFITS OF PROTON THERAPY FINAL REPORT

16 Exhibit 12a. EPIC Summary Scores by Length of Time since Treatment. 0 years (n=265) 1 year (n=352) Years Since Proton Therapy 2 years (n=305) 3 years (n=236) 4 years (n=144) 5 years (n=138) 6 years+ (n=497) Urinary Summary 87.3* * Bowel Summary Sexual Summary * Hormonal Summary *p <0.05 Exhibit 12b. EPIC Summary and Subscale Scores by Length of Time since Treatment. 0 years (n=265) 1 year (n=143) Years Since Proton Therapy 2 years (n=261) 3 years (n=385) 4 years (n=307) 5 years (n=76) 6 years + (n=308) Urinary Summary 87.3* * Urinary Function Urinary Bother 83.0* Urinary Irritative 85.2* Urinary Incontinence * Bowel Summary Bowel Function Bowel Bother Sexual Summary * Sexual Function * * Sexual Bother * * Hormonal Summary Hormonal Function Hormonal Bother Satisfaction AUA Symptom Score 7.9* SF-12 PCS * SF-12 MCS *p<0.05 PROSTATE CANCER PATIENTS REPORT ON BENEFITS OF PROTON THERAPY FINAL REPORT

17 Satisfaction with Proton Therapy As seen in Exhibits 13 and 14, patients were satisfied with their proton therapy experience, both by time since treatment completion and by modality. A vast majority (98.5 percent) of respondents rated their proton therapy experience as Excellent or Good, while less than one percent of respondents rated their experience as Poor. Satisfaction did not differ significantly by time elapsed since receiving treatment, or by treatment modality, although those receiving only proton therapy were slightly more likely to rate their proton therapy experience as Excellent rather than Good (Exhibit 14). Exhibit 13. Overall, how would you rate your proton experience? (By Time Since Completion of Therapy) Poor Fair Good Excellent Total Years since proton therapy n % n % n % n % n 0 years 0 0.0% 3 1.2% % % years 4 1.1% 3 0.9% % % years 1 0.3% 4 1.3% % % years 0 0.0% 0 0.0% % % years 1 0.7% 3 2.0% % % years 1 0.7% 1 0.7% % % years % 2 0.4% % % 495 Total % % % % 1911 Exhibit 14. Overall, how would you rate your proton experience? (By Treatment Modality) Poor Fair Good Excellent Total Treatment Modality n % n % n % n % n Only Receiving Proton Therapy % % % % 1485 Receiving Proton and Photon Therapy 1 0.5% 1 0.5% % % 143 Receiving Proton and Hormone Therapy 1 0.3% 2 0.7% % % 300 Approximately 99 percent of respondents stated that they believed they made the best treatment decision for themselves, both by time since completion of therapy (Exhibit 15), or by treatment modality (Exhibit 16). Additionally, 98 percent reported that they had recommended proton therapy to others (Exhibits 17 and 18). PROSTATE CANCER PATIENTS REPORT ON BENEFITS OF PROTON THERAPY FINAL REPORT

18 Exhibit 15. Do you feel you made the best treatment decision for yourself? (By Time Since Completion of Therapy) Yes No Total Years since proton therapy n % n % n 0 years % 0 0.0% years % 3 0.9% years % 2 0.7% years % 1 0.4% years % 5 3.5% years % 4 2.9% years % % 492 Total % % 1901 Exhibit 16. Do you feel you made the best treatment decision for yourself? (By Treatment Modality) Yes No Total Treatment Modality n % n % n Only Receiving Proton Therapy % % 1475 Receiving Proton and Photon Therapy % 7 3.9% 179 Receiving Proton and Hormone Therapy % 5 1.7% 297 Exhibit 17. Have you recommended proton therapy to others? (By Time Since Completion of Therapy) Yes No Total Years since proton therapy n % n % n 0 years % % years % % years % 7 2.3% years % 2 0.9% years % 2 1.4% years % 1 0.7% years % 6 1.2% 493 Total % % 1908 PROSTATE CANCER PATIENTS REPORT ON BENEFITS OF PROTON THERAPY FINAL REPORT

19 Exhibit 18. Have you recommended proton therapy to others? (By Treatment Modality) Yes No Total Treatment Modality n % n % n Only Receiving Proton Therapy % % 1480 Receiving Proton and Photon Therapy % 2 1.1% 179 Receiving Proton and Hormone Therapy % 5 1.7% 299 Exhibit 19 shows that 81.5% of patients reported being Extremely Satisfied with their treatment. Patients 5 years since therapy were less likely to report being Extremely Satisfied, but were more likely to report being Satisfied. Exhibit 20 shows that proton only patients were more likely to respond that they were Extremely Satisfied with their treatment. Exhibit 19. Overall, how satisfied are you with the treatment you received for your prostate cancer? (By Time Since Completion of Treatment) Extremely Dissatisfied Dissatisfied Uncertain Satisfied Extremely Satisfied Years since proton therapy n % n % n % n % n % n 0 years 2 0.8% 0 0.0% % % % years 2 0.6% 1 0.3% % % % years 2 0.7% 2 0.7% 7 2.4% % % years 0 0.0% 0 0.0% 9 3.8% % % years 1 0.7% 1 0.7% 4 2.8% % % years 2 1.5% 0 0.0% 5 3.7% % % years % 6 1.2% % % % 488 Total % % % % % 1898 Total Exhibit 20. Overall, how satisfied are you with the treatment you received for your prostate cancer? (By Treatment Modality) Extremely Dissatisfied Dissatisfied Uncertain Satisfied Extremely Satisfied Treatment Modality n % n % n % n % n % n Only Receiving Proton Therapy 8 0.5% 8 0.5% % % % 1460 Receiving Proton and Photon Therapy 1 0.6% 1 0.6% 8 4.5% % % 179 Receiving Proton and Hormone Therapy 1 0.3% 1 0.3% % % % 296 Total PROSTATE CANCER PATIENTS REPORT ON BENEFITS OF PROTON THERAPY FINAL REPORT

20 Quality of Life Ninety-one percent of patients reported that their quality of life was better (29.0 percent) or the same (62.1 percent) today as it was before their treatment, while only nine percent reported that their quality of life had declined (Exhibit 21). This differed across treatment modalities with proton only therapy patients reporting the best quality of life following treatment (92.6 percent reporting better or same). Eighteen percent of respondents who received photon therapy in addition to proton therapy and fourteen percent receiving hormone therapy in addition to proton therapy rated their QOL as worse today than before treatment. In contrast, only seven percent of respondents receiving only proton therapy reported their QOL as worse today than before treatment (Exhibit 22). Additionally, those rating their quality of life as Better Than appeared to decline substantially after five years post-treatment (Exhibit 21). Exhibit 21. How would you describe your QOL today- better than, same as, or worse than before the treatment? (By Time Since Completion of Treatment) Better Than Same As Worse Than Total Years since proton therapy n % n % n % n 0 years % % % years % % % years % % % years % % % years % % % years % % % years % % % 492 Total % % % 1899 Exhibit 22. How would you describe your QOL today- better than, same as, or worse than before the treatment? (By Treatment Modality) Better Than Same As Worse Than Total Treatment Modality n % n % n % n Only Receiving Proton Therapy % % % 1473 Receiving Proton and Photon Therapy % % % 182 Receiving Proton and Hormone Therapy % % % 300 PROSTATE CANCER PATIENTS REPORT ON BENEFITS OF PROTON THERAPY FINAL REPORT

21 Physical and Emotional Functioning Few studies have empirically examined the prevalence of depression in men with prostate cancer. However, anxiety about cancer as a diagnosis, lack of awareness of treatment options, medical complications, fear of death, and financial burdens are some of the factors that have been shown to lead to depression among prostate cancer patients. 3 Men with prostate cancer at risk for depression include those with advanced prostate cancer, prominent pain symptoms, side effects of treatment and a previous history of clinical depression. 4 Depression has also been strongly correlated to fatigue and pain as symptoms of prostate cancer. 5 Based on survey data, over 93 percent of patients who were treated with proton therapy reported that physical health or emotional problems did not interfere, or interfered little with their social activities (Exhibit 23). Interference was less between two years and five years post treatment, before declining in the six years or more post treatment category. Exhibit 24 shows that 93.5 percent of patients receiving proton only treatment had little or none of their time being affected by physical health or emotional problems, vs percent for proton plus photon therapy or 91.0 percent for proton plus hormonal therapy. 3 Pasquini M, Biondi M. (2007). Depression in cancer patients: a critical review. Clin Pract Epidemiol Ment Health 3: Cliff AM, McDonagh P. (2000). Psychosocial morbidity in prostate cancer II: a comparison of patients and partners. BJU Int 86: Heim HE, Oei TPS. (1993). Comparison of prostate cancer with and without pain. Pain 53: PROSTATE CANCER PATIENTS REPORT ON BENEFITS OF PROTON THERAPY FINAL REPORT

22 Exhibit 23. During the PAST 4 WEEKS, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting with friends, etc.)? (By Time Since Completion of Treatment) All of the Time Most of the Time Some of the Time A Little of the Time None of the Time Years since proton therapy n % n % n % n % n % n 0 years 5 2.0% 1 0.4% % % % years 4 1.1% 2 0.6% % % % years 4 1.3% 4 1.3% 6 2.0% % % years 1 0.4% 1 0.4% % % % years 0 0.0% 0 0.0% 6 4.2% % % years 0 0.0% 0 0.0% 6 4.4% % % years % 7 1.4% % % % 496 Total % % % % % 1920 Total Exhibit 24. During the PAST 4 WEEKS, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting with friends, etc.)? (By Treatment Modality) All of the Time Most of the Time Some of the Time A Little of the Time None of the Time Treatment Modality n % n % n % n % n % n Only Receiving Proton Therapy % % % % % 1483 Receiving Proton and Photon Therapy 2 1.1% 2 1.1% % % % 182 Receiving Proton and Hormone Therapy 4 1.3% 2 0.7% % % % 301 Total PROSTATE CANCER PATIENTS REPORT ON BENEFITS OF PROTON THERAPY FINAL REPORT Dobson Davanzo

23 Discussion Between the years 1991 to 2010, approximately 10,000 patients were treated for prostate cancer with proton therapy across the 10 currently operating proton centers in the United States. This study captures close to 20 percent of this population across all centers, with patients having varying ages, clinical conditions, time elapsed since treatment, etc. Proton therapy is unique in that it targets specific tissues, and minimizes damage to healthy tissues, thus minimizing side effects. This differs from other treatments such as photon beam radiation, which often causes negative side effects that affect a patient s quality of life post- treatment. Our results substantiate this anecdotal information, as we found that patients receiving proton therapy for the treatment of prostate cancer were extremely satisfied with their treatment, and reported similar quality of life post-treatment to healthy individuals who have not been diagnosed with prostate cancer. In comparison to patients receiving other treatments in addition to proton therapy (hormone or photon therapy), proton only therapy patients reported that urinary, sexual, and bowel problems interfered less with their life through reporting higher HRQOL EPIC scores in these areas compared to individuals receiving other forms of treatment. PROSTATE CANCER PATIENTS REPORT ON BENEFITS OF PROTON THERAPY FINAL REPORT

PSA Screening for Prostate Cancer Information for Care Providers

PSA Screening for Prostate Cancer Information for Care Providers All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits

More information

7. Prostate cancer in PSA relapse

7. Prostate cancer in PSA relapse 7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined

More information

Quality of Life After Radical Prostatectomy

Quality of Life After Radical Prostatectomy Quality of Life After Radical Prostatectomy Bernard H. Bochner, MD FACS Attending Surgeon, Urology Service Vice Chairman, Department of Surgery Memorial Sloan-Kettering Cancer Center Quality of Life After

More information

Summary of Harms from Screening and Treatment for Prostate Cancer

Summary of Harms from Screening and Treatment for Prostate Cancer DRAFT: Advice from Dr John Childs MoH advisor Summary of Harms from Screening and Treatment for Prostate Cancer There are minimal risks directly attributable to PSA testing or transrectal ultrasound (TRUS)

More information

da Vinci Prostatectomy Information Guide (Robotically-Assisted Radical Prostatectomy)

da Vinci Prostatectomy Information Guide (Robotically-Assisted Radical Prostatectomy) da Vinci Prostatectomy Information Guide (Robotically-Assisted Radical Prostatectomy) Prostate Cancer Overview Prostate cancer is a disease in which malignant (cancer) cells form in the tissues of the

More information

da Vinci Prostatectomy (Robotically Assisted Radical Prostatectomy)

da Vinci Prostatectomy (Robotically Assisted Radical Prostatectomy) Peninsula Urology Center, Inc. Dieter Bruno, M.D, F.A.C.S Chris Threat, M.D. 3351 El Camino. Real, Suite 101 Atherton, CA 94027 (650) 306-1016 dbrunomd@pucenter.com http://www.pucenter.com/ da Vinci Prostatectomy

More information

Proton Therapy for Prostate Cancer: Your Questions, Our Answers.

Proton Therapy for Prostate Cancer: Your Questions, Our Answers. Proton Therapy for Prostate Cancer: Your Questions, Our Answers. When you re looking for the right treatment for your prostate cancer, nothing s more important than accurate information. Read on, and learn

More information

Prostate Cancer. There is no known association with an enlarged prostate or benign prostatic hyperplasia (BPH).

Prostate Cancer. There is no known association with an enlarged prostate or benign prostatic hyperplasia (BPH). Prostate Cancer Definition Prostate cancer is cancer that starts in the prostate gland. The prostate is a small, walnut-sized structure that makes up part of a man's reproductive system. It wraps around

More information

Care Guide: Cancer Distress Management

Care Guide: Cancer Distress Management Screening Tools for Measuring Distress Care Guide: Cancer Distress Management Instructions: Circle the number between [0 10] that best describes your patient s level of distress over the past week, including

More information

Prostate Cancer. More information for men and their families and whanau. Stay well for your family and whanau

Prostate Cancer. More information for men and their families and whanau. Stay well for your family and whanau Prostate Cancer More information for men and their families and whanau Stay well for your family and whanau Contents What is the prostate? 4 What is prostate cancer? 5 How common is prostate cancer? 5

More information

Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50

Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 General Data Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 The vast majority of the patients in this study were diagnosed

More information

AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options

AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options INTRODUCTION This booklet describes how prostate cancer develops, how it affects the body and the current treatment methods. Although

More information

Prostate cancer screening. It s YOUR decision!

Prostate cancer screening. It s YOUR decision! Prostate cancer screening It s YOUR decision! For many years now, a test has been available to screen for. The test is called the prostate-specific antigen blood test (or PSA test). It is used in combination

More information

BACKGROUND. ADA and the European Association recently issued a consensus algorithm for management of type 2 diabetes

BACKGROUND. ADA and the European Association recently issued a consensus algorithm for management of type 2 diabetes BACKGROUND More than 25% of people with diabetes take insulin ADA and the European Association recently issued a consensus algorithm for management of type 2 diabetes Insulin identified as the most effective

More information

Oncology Nursing Society Annual Progress Report: 2008 Formula Grant

Oncology Nursing Society Annual Progress Report: 2008 Formula Grant Oncology Nursing Society Annual Progress Report: 2008 Formula Grant Reporting Period July 1, 2011 June 30, 2012 Formula Grant Overview The Oncology Nursing Society received $12,473 in formula funds for

More information

Information for Men Receiving Radiation and Hormone Treatments for Prostate Cancer

Information for Men Receiving Radiation and Hormone Treatments for Prostate Cancer Information for Men Receiving Radiation and Hormone Treatments for Prostate Cancer Treatment Plan Stage of prostate cancer: RADIATION THERAPY Radiation Treatments: Date for planning CT: Date to start radiation

More information

East Lancashire Surgical Robot

East Lancashire Surgical Robot East Lancashire Surgical Robot For ALL patients in Lancashire Prostate cancer claims the life of one man every hour and by 2030 will be the most common cancer; it is already the most common male cancer.

More information

Questions to ask my doctor: About prostate cancer

Questions to ask my doctor: About prostate cancer Questions to ask my doctor: About prostate cancer Being diagnosed with prostate cancer can be scary and stressful. You probably have a lot of questions and concerns. Learning about the disease, how it

More information

Treating Localized Prostate Cancer A Review of the Research for Adults

Treating Localized Prostate Cancer A Review of the Research for Adults Treating Localized Prostate Cancer A Review of the Research for Adults Is this information right for me? Yes, this information is right for you if: Your doctor * said all tests show you have localized

More information

FAQ About Prostate Cancer Treatment and SpaceOAR System

FAQ About Prostate Cancer Treatment and SpaceOAR System FAQ About Prostate Cancer Treatment and SpaceOAR System P. 4 Prostate Cancer Background SpaceOAR Frequently Asked Questions (FAQ) 1. What is prostate cancer? The vast majority of prostate cancers develop

More information

ANNOTATED BIBLIOGRAPHY PROSTATE CANCER CARE

ANNOTATED BIBLIOGRAPHY PROSTATE CANCER CARE ANNOTATED BIBLIOGRAPHY PROSTATE CANCER CARE This annotated bibliography was developed as part of ACCC s Prostate Cancer Projects: Developing Tools and Measuring Effectiveness educational project. A literature

More information

CYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results. Alan Katz MD JD Flushing, NY USA

CYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results. Alan Katz MD JD Flushing, NY USA CYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results Alan Katz MD JD Flushing, NY USA Prostate Ablative Therapy Over the last 10 years our therapy has improved bned rates for LDR/HDR

More information

4/8/13. Pre-test Audience Response. Prostate Cancer 2012. Screening and Treatment of Prostate Cancer: The 2013 Perspective

4/8/13. Pre-test Audience Response. Prostate Cancer 2012. Screening and Treatment of Prostate Cancer: The 2013 Perspective Pre-test Audience Response Screening and Treatment of Prostate Cancer: The 2013 Perspective 1. I do not offer routine PSA screening, and the USPSTF D recommendation will not change my practice. 2. In light

More information

Questions to Ask My Doctor About Prostate Cancer

Questions to Ask My Doctor About Prostate Cancer Questions to Ask My Doctor Being told you have prostate cancer can be scary and stressful. You probably have a lot of questions and concerns. Learning about the disease, how it s treated, and how this

More information

Michigan Depression Outreach and Collaborative Care (MDOCC) Over the past two weeks how often have you been bothered by any the following problems?

Michigan Depression Outreach and Collaborative Care (MDOCC) Over the past two weeks how often have you been bothered by any the following problems? Michigan Depression Outreach and Collaborative Care (MDOCC) PHQ-9 Over the past two weeks how often have you been bothered by any the following problems? 1. Little interest or pleasure in doing things?

More information

Early Prostate Cancer: Questions and Answers. Key Points

Early Prostate Cancer: Questions and Answers. Key Points CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Early Prostate Cancer:

More information

TITLE: The Impact Of Prostate Cancer Treatment-Related Symptoms On Low-Income Latino Couples

TITLE: The Impact Of Prostate Cancer Treatment-Related Symptoms On Low-Income Latino Couples AD Award Number: W81WH-07-1-0069 TITLE: The Impact Of Prostate Cancer Treatment-Related Symptoms On Low-Income Latino Couples PRINCIPAL INVESTIGATOR: Sally L. Maliski, Ph.D., R.N. CONTRACTING ORGANIZATION:

More information

TO SCREEN OR NOT TO SCREEN: THE PROSTATE CANCER

TO SCREEN OR NOT TO SCREEN: THE PROSTATE CANCER TO SCREEN OR NOT TO SCREEN: THE PROSTATE CANCER DILEMMA Thomas J Stormont MD January 2012 http://www.youtube.com/watch?v=8jd 7bAHVp0A&feature=related related INTRODUCTION A government health panel (the

More information

The PSA Test for Prostate Cancer Screening:

The PSA Test for Prostate Cancer Screening: For more information, please contact your local VA Medical Center or Health Clinic. U.S. Department of Veterans Affairs Veterans Health Administration Patient Care Services Health Promotion and Disease

More information

HEALTH 4 DEPRESSION, OTHER EMOTIONS, AND HEALTH

HEALTH 4 DEPRESSION, OTHER EMOTIONS, AND HEALTH HEALTH 4 DEPRESSION, OTHER EMOTIONS, AND HEALTH GOALS FOR LEADERS To talk about the connection between certain emotions (anger, anxiety, fear, and sadness and health) To talk about ways to manage feelings

More information

Oncology Nursing Society Annual Progress Report: 2008 Formula Grant

Oncology Nursing Society Annual Progress Report: 2008 Formula Grant Oncology Nursing Society Annual Progress Report: 2008 Formula Grant Reporting Period July 1, 2009 June 30, 2010 Formula Grant Overview The Oncology Nursing Society received $12,473 in formula funds for

More information

Prostate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40.

Prostate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40. A.D.A.M. Medical Encyclopedia. Prostate cancer Cancer - prostate; Biopsy - prostate; Prostate biopsy; Gleason score Last reviewed: October 2, 2013. Prostate cancer is cancer that starts in the prostate

More information

An Introduction to PROSTATE CANCER

An Introduction to PROSTATE CANCER An Introduction to PROSTATE CANCER Being diagnosed with prostate cancer can be a life-altering experience. It requires making some very difficult decisions about treatments that can affect not only the

More information

Management of Localized Prostate Cancer. Treatment Options

Management of Localized Prostate Cancer. Treatment Options Management of Localized Prostate Cancer Surgery James A. Eastham, MD Chief, Urology Service Memorial lsloan Kettering Cancer Center Treatment Options 1. Active surveillance/watchful waiting 2. Focal therapy

More information

Cooled ThermoTherapy TM

Cooled ThermoTherapy TM Are BPH Medications Weighing You Down? Think Outside the Pillbox Cooled ThermoTherapy TM A non-surgical, 30 minute in-office treatment that provides long-term relief from BPH symptoms and urinary obstruction

More information

Cancer research in the Midland Region the prostate and bowel cancer projects

Cancer research in the Midland Region the prostate and bowel cancer projects Cancer research in the Midland Region the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland MoH/HRC Cancer Research agenda Lung cancer Palliative care Prostate

More information

Complementary and alternative medicine use in Chinese women with breast cancer: A Taiwanese survey

Complementary and alternative medicine use in Chinese women with breast cancer: A Taiwanese survey Complementary and alternative medicine use in Chinese women with breast cancer: A Taiwanese survey Dr Fang-Ying (Sylvia) Chu Department of Nursing, Tzu Chi College of Technology, Hua Lien, Taiwan 1 BACKGROUND

More information

THE FOOT HEALTH STATUS QUESTIONNAIRE

THE FOOT HEALTH STATUS QUESTIONNAIRE THE FOOT HEALTH STATUS QUESTIONNAIRE Version 1.03 Thank you for taking the time to fill out this important questionnaire. The answers you provide will help your podiatrist to understand how to care for

More information

Screening for Prostate Cancer

Screening for Prostate Cancer Cancer Expert Working Group on Cancer Prevention and Screening Screening for Prostate Cancer Information for men and their families 1 What is the prostate? 2 What is prostate cancer? prostate The prostate

More information

Advances in Diagnostic and Molecular Testing in Prostate Cancer

Advances in Diagnostic and Molecular Testing in Prostate Cancer Advances in Diagnostic and Molecular Testing in Prostate Cancer Ashley E. Ross MD PhD Assistant Professor Urology, Oncology, Pathology Johns Hopkins School of Medicine September 24, 2015 1 Disclosures

More information

A Gene Expression Test to Predict Prostate Cancer Aggressiveness. Use Prolaris as a guide in your medical and surgical management

A Gene Expression Test to Predict Prostate Cancer Aggressiveness. Use Prolaris as a guide in your medical and surgical management A Gene Expression Test to Predict Prostate Cancer Aggressiveness Use Prolaris as a guide in your medical and surgical management What is Prolaris? A direct molecular measure of prostate cancer tumor biology

More information

Caregiving Impact on Depressive Symptoms for Family Caregivers of Terminally Ill Cancer Patients in Taiwan

Caregiving Impact on Depressive Symptoms for Family Caregivers of Terminally Ill Cancer Patients in Taiwan Caregiving Impact on Depressive Symptoms for Family Caregivers of Terminally Ill Cancer Patients in Taiwan Siew Tzuh Tang, RN, DNSc Associate Professor, School of Nursing Chang Gung University, Taiwan

More information

P R O S T A T E C A N C E R

P R O S T A T E C A N C E R The Management of Localized P R O S T A T E C A N C E R Patient Guide Based on recommendations from the Prostate Cancer Clinical Guideline Panel of the American Urological Association The AUA Foundation

More information

2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER

2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER 2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER Humboldt County is located on the Redwood Coast of Northern California. U.S census data for 2010 reports county population at 134,623, an increase of

More information

News Report No More PSA Testing? What Are They Thinking?

News Report No More PSA Testing? What Are They Thinking? News Report No More PSA Testing? What Are They Thinking? By Bob Marckini This was going to be a short article in this month s BOB Tales newsletter, but based on the considerable follow up media coverage

More information

Coding for Prostate Cancer

Coding for Prostate Cancer Coding for Prostate Cancer Tracy L. Burney, M.D. Health First Physicians Urology September 19, 2012 Prostate Cancer Basics What is the Prostate and What Does it do? Walnut sized organ found only in men.

More information

Follow-up after prostate cancer treatment What happens next?

Follow-up after prostate cancer treatment What happens next? Follow-up after prostate cancer treatment What happens next? 2 Follow-up after prostate cancer treatment About this booklet If you ve had treatment aimed at getting rid of your prostate cancer, such as

More information

Quality of Life of Children

Quality of Life of Children Quality of Life of Children with Mental Illness Martha J. Molly Faulkner, PhD, CNP, LISW University of New Mexico Health Sciences Center Children s Psychiatric Center Outpatient Services Objectives History

More information

PATIENT GUIDE. Localized Prostate Cancer

PATIENT GUIDE. Localized Prostate Cancer PATIENT GUIDE Localized Prostate Cancer The prostate* is part of the male reproductive system. It is about the same size as a walnut and weighs about an ounce. As pictured in Figure 1, the prostate is

More information

Us TOO University Presents: Understanding Diagnostic Testing

Us TOO University Presents: Understanding Diagnostic Testing Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by

More information

Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36)

Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36) Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36) bout: The SF-36 is an indicator overall health status. Items: 10 Reliability: Most se studies that examined reliability SF_36 have

More information

Instruments Available for Use in Assessment Center

Instruments Available for Use in Assessment Center Instruments Available for Use in Assessment Center The Assessment Center Instrument Library includes instruments from PROMIS, Neuro QoL, NIH Toolbox and Health LiTT. All instruments are available for use

More information

Partners HealthCare Innovation in Service to the Mission. Gary L. Gottlieb, MD, MBA

Partners HealthCare Innovation in Service to the Mission. Gary L. Gottlieb, MD, MBA Partners HealthCare Innovation in Service to the Mission Gary L. Gottlieb, MD, MBA The Mission Patient Care Discovery Teaching Community Our Clinical Objectives To provide the best health care to patients

More information

Introduction to Statistics Used in Nursing Research

Introduction to Statistics Used in Nursing Research Introduction to Statistics Used in Nursing Research Laura P. Kimble, PhD, RN, FNP-C, FAAN Professor and Piedmont Healthcare Endowed Chair in Nursing Georgia Baptist College of Nursing Of Mercer University

More information

Robotic Radical Prostatectomy: What s s the Advantage? Matthew T. Gettman, M.D. Associate Professor Department of Urology

Robotic Radical Prostatectomy: What s s the Advantage? Matthew T. Gettman, M.D. Associate Professor Department of Urology Robotic Radical Prostatectomy: What s s the Advantage? Matthew T. Gettman, M.D. Associate Professor Department of Urology Prostate Cancer Epidemiology: 2009 Estimated new cases: 230,000 Estimated deaths:

More information

Comparison of Cancer Patients Treated in Hospital Outpatient Departments and Physician Offices Final Report

Comparison of Cancer Patients Treated in Hospital Outpatient Departments and Physician Offices Final Report Comparison of Cancer Patients Treated in Hospital Outpatient Departments and Physician Offices Final Report Prepared for: American Hospital Association November 13, 2014 Berna Demiralp, PhD Delia Belausteguigoitia

More information

Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward

Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward 33 rd Annual Internal Medicine Update December 5, 2015 Ryan C. Hedgepeth, MD, MS Chief of

More information

1. What is the prostate-specific antigen (PSA) test?

1. What is the prostate-specific antigen (PSA) test? 1. What is the prostate-specific antigen (PSA) test? Prostate-specific antigen (PSA) is a protein produced by the cells of the prostate gland. The PSA test measures the level of PSA in the blood. The doctor

More information

Quality of Life of Cancer Survivors in England. Report on a pilot survey using Patient Reported Outcome Measures (PROMS)

Quality of Life of Cancer Survivors in England. Report on a pilot survey using Patient Reported Outcome Measures (PROMS) Quality of Life of Cancer Survivors in England Report on a pilot survey using Patient Reported Outcome Measures (PROMS) December 2012 DH InformatIon reader BoX Policy Clinical Estates HR/Workforce Commissioner

More information

Radiation Therapy for Prostate Cancer: Treatment options and future directions

Radiation Therapy for Prostate Cancer: Treatment options and future directions Radiation Therapy for Prostate Cancer: Treatment options and future directions David Weksberg, M.D., Ph.D. PinnacleHealth Cancer Institute September 12, 2015 Radiation Therapy for Prostate Cancer: Treatment

More information

Thomas A. Kollmorgen, M.D. Oregon Urology Institute

Thomas A. Kollmorgen, M.D. Oregon Urology Institute Thomas A. Kollmorgen, M.D. Oregon Urology Institute None 240,000 new diagnosis per year, and an estimated 28,100 deaths (2012) 2 nd leading cause of death from cancer in U.S.A. Approximately 1 in 6 men

More information

A Woman s Guide to Prostate Cancer Treatment

A Woman s Guide to Prostate Cancer Treatment A Woman s Guide to Prostate Cancer Treatment Supporting the man in your life Providing prostate cancer support and resources for women and families WOMEN AGAINST PROSTATE CANCER A Woman s Guide to Prostate

More information

Prostate Cancer Treatment: What s Best for You?

Prostate Cancer Treatment: What s Best for You? Prostate Cancer Treatment: What s Best for You? Prostate Cancer: Radiation Therapy Approaches I. Choices There is really a variety of options in prostate cancer management overall and in radiation therapy.

More information

Prostate Cancer. Understanding your diagnosis

Prostate Cancer. Understanding your diagnosis Prostate Cancer Understanding your diagnosis Prostate Cancer Understanding your diagnosis When you first hear that you have cancer, you may feel alone and afraid. You may be overwhelmed by the large amount

More information

Tara Stevermuer (MAppStat), Centre for Health Service Development, University of Wollongong.

Tara Stevermuer (MAppStat), Centre for Health Service Development, University of Wollongong. ENAR - PAIN RELIEF THAT S FAST AND LASTS Tara Stevermuer (MAppStat), Centre for Health Service Development, University of Wollongong. Introducing ENAR The ENAR (Electro-Neuro-Adaptive-Regulator) is a Russian

More information

Bladder cancer treatment decision, management, and psychosocial outcomes: Results of patients interviews

Bladder cancer treatment decision, management, and psychosocial outcomes: Results of patients interviews Bladder cancer treatment decision, management, and psychosocial outcomes: Results of patients interviews Nihal Mohamed & Michael Diefenbach Department of Urology Mount Sinai School of Medicine Study Questions

More information

The Business of Prostate Cancer Care: A Clinician-Researcher s Perspective

The Business of Prostate Cancer Care: A Clinician-Researcher s Perspective The Business of Prostate Cancer Care: A Clinician-Researcher s Perspective David F. Penson, MD, MPH Departments of Urology and Preventive Medicine Keck School of Medicine University of Southern California

More information

Global Economic Impact of Multiple Sclerosis

Global Economic Impact of Multiple Sclerosis Global Economic Impact of Multiple Sclerosis May 2010 Literature Review Executive Summary Prepared for Multiple Sclerosis International Federation London, United Kingdom Prepared by Michael Trisolini,

More information

CONTENTS: WHAT S IN THIS BOOKLET

CONTENTS: WHAT S IN THIS BOOKLET Q Questions & A & Answers About Your Prostate Having a biopsy test to find out if you may have prostate cancer can bring up a lot of questions. This booklet will help answer those questions. CONTENTS:

More information

GHQ SCORES PREDICT UNIQUELY SUBSEQUENT SURVIVAL IN SUCCESSFULLY TREATED HEAD AND NECK CANCER PATIENTS: A PROSPECTIVE COHORT STUDY

GHQ SCORES PREDICT UNIQUELY SUBSEQUENT SURVIVAL IN SUCCESSFULLY TREATED HEAD AND NECK CANCER PATIENTS: A PROSPECTIVE COHORT STUDY GHQ SCORES PREDICT UNIQUELY SUBSEQUENT SURVIVAL IN SUCCESSFULLY TREATED HEAD AND NECK CANCER PATIENTS: A PROSPECTIVE COHORT STUDY Anne K.H. Aarstad 2,3, Arild A Osthus 1, Jan Olofsson 1,2, Hans J. Aarstad

More information

Breast Cancer in Young Women: Quality of Life and Survivorship

Breast Cancer in Young Women: Quality of Life and Survivorship Breast Cancer in Young Women: Quality of Life and Survivorship Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute Brigham and Women s Hospital Harvard Medical School Breast Cancer in Young Women is

More information

HEALTH NEWS PROSTATE CANCER THE PROSTATE

HEALTH NEWS PROSTATE CANCER THE PROSTATE HEALTH NEWS PROSTATE CANCER THE PROSTATE Prostate comes from the Greek meaning to stand in front of ; this is very different than prostrate which means to lie down flat. The prostate is a walnut-sized

More information

PEER REVIEW HISTORY ARTICLE DETAILS

PEER REVIEW HISTORY ARTICLE DETAILS PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)

More information

CRITÉRIOS DE AVALIAÇÃO DE QUALIDADE DE VIDA

CRITÉRIOS DE AVALIAÇÃO DE QUALIDADE DE VIDA CRITÉRIOS DE AVALIAÇÃO DE QUALIDADE DE VIDA S1 SF36 General Health Survey Patient Name Patient ID Study Name Study Number Date / / Side Right Left Filled in by: Operating Dr. Other MD Research Assistant

More information

The following document includes information about:

The following document includes information about: Patient information WHAT TO EXPECT WHILE RECEIVING RADIATION THERAPY FOR PROSTATE CANCER Oncology Vitalité Zone : 1B 4 5 6 Facility : Dr. Léon-Richard Oncology Centre The following document includes information

More information

Female Urinary Disorders and Pelvic Organ Prolapse

Female Urinary Disorders and Pelvic Organ Prolapse Female Urinary Disorders and Pelvic Organ Prolapse Richard S. Bercik, M.D. Director, Division of Urogynecology & Reconstruction Pelvic Surgery Department of Obstetrics, Gynecology & Reproductive Sciences

More information

Why is radiation therapy used to treat prostate cancer? Is there anything that I have to do before my treatment planning appointment?

Why is radiation therapy used to treat prostate cancer? Is there anything that I have to do before my treatment planning appointment? 2015 Information for Patients Receiving Radiation Therapy: External Beam Treatment for Prostate Cancer Why is radiation therapy used to treat prostate cancer? Prostate cancer may be treated with a combination

More information

Prostate Cancer Treatment

Prostate Cancer Treatment Scan for mobile link. Prostate Cancer Treatment Prostate cancer is a tumor of the prostate gland, which is located in front of the rectum and below the bladder. Your doctor may perform a physical exam,

More information

Palo Alto Medical Foundation s Prostate Cancer Care Program

Palo Alto Medical Foundation s Prostate Cancer Care Program Palo Alto Medical Foundation s Prostate Cancer Care Program Patient-centered care in a California multispecialty group practice by Frank delarama, RN, MSN, AOCNS; Gordon Ray, MD; and Daniel Yao, MD Our

More information

Dealing with Erectile Dysfunction During and After Prostate Cancer Treatment For You and Your Partner

Dealing with Erectile Dysfunction During and After Prostate Cancer Treatment For You and Your Partner Dealing with Erectile Dysfunction During and After Prostate Cancer Treatment For You and Your Partner The following information is based on the general experiences of many prostate cancer patients. Your

More information

Prostate Cancer Screening

Prostate Cancer Screening Prostate Cancer Screening The American Cancer Society and Congregational Health Ministry Team June Module To access this module via the Web, visit www.cancer.org and type in congregational health ministry

More information

Chemobrain. Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015

Chemobrain. Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015 Chemobrain Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015 Terminology Chemotherapy-associated cognitive dysfunction Post-chemotherapy cognitive impairment Cancer treatment-associated cognitive

More information

Kanıt: Klinik çalışmalarda ZYTIGA

Kanıt: Klinik çalışmalarda ZYTIGA mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen

More information

Defining Sexual Outcomes after Treatment for Localized Prostate Carcinoma

Defining Sexual Outcomes after Treatment for Localized Prostate Carcinoma 1773 Defining Sexual Outcomes after Treatment for Localized Prostate Carcinoma Leslie R. Schover, Ph.D. 1 Rachel T. Fouladi, Ph.D. 1 Carla L. Warneke, M.S. 1 Leah Neese, M.A. 1 Eric A. Klein, M.D. 2 Craig

More information

da Vinci Prostatectomy

da Vinci Prostatectomy da Vinci Prostatectomy Changing the Experience of Prostate Surgery Are you a candidate for the latest treatment option for prostate cancer? Your doctor may be able to offer you a new, minimally invasive

More information

Patient Questionnaire for Men

Patient Questionnaire for Men Patient Questionnaire for Men Please fill out the following questionnaire to the best of your ability prior to your first appointment. Your physical therapist will review your responses during your initial

More information

Kantar Health, New York, NY 2 Pfizer Inc, New York, NY. Experiencing depression. Not experiencing depression

Kantar Health, New York, NY 2 Pfizer Inc, New York, NY. Experiencing depression. Not experiencing depression NR1-62 Depression, Quality of Life, Work Productivity and Resource Use Among Women Experiencing Menopause Jan-Samuel Wagner, Marco DiBonaventura, Jose Alvir, Jennifer Whiteley 1 Kantar Health, New York,

More information

Prostate Cancer Screening

Prostate Cancer Screening Prostate Cancer Screening Bruce L. Houghton, MD Associate Professor of Medicine Division of General Medicine Department of Internal Medicine Creighton University School of Medicine http://en.wikipedia.org/wiki/image:prostatelead.jpg

More information

Subcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors. 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D.

Subcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors. 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D. Subcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D., FACS Learning Objectives After reading and reviewing this

More information

Proton Therapy for Prostate Cancer

Proton Therapy for Prostate Cancer Proton Therapy for Prostate Cancer Andrew K. Lee, MD, MPH Director, Proton Therapy Center Associate Professor Department of Radiation Oncology M.D. Anderson Cancer Center Randomized studies showing benefit

More information

Screening for Prostate Cancer

Screening for Prostate Cancer Screening for Prostate Cancer It is now clear that screening for Prostate Cancer discovers the disease at an earlier and more curable stage. It is not yet clear whether this translates into reduced mortality

More information

Transrectal Ultrasound (Trus) Guided Prostate Biopsies Urology Patient Information Leaflet

Transrectal Ultrasound (Trus) Guided Prostate Biopsies Urology Patient Information Leaflet Transrectal Ultrasound (Trus) Guided Prostate Biopsies Urology Patient Information Leaflet Page 1 What is the purpose of my appointment? Your doctor has informed us that you have an elevated Prostate Specific

More information

Erectile function and quality of life after interstitial radiation therapy for prostate cancer

Erectile function and quality of life after interstitial radiation therapy for prostate cancer (2000) 12, Suppl 3, S18±S24 ß 2000 Macmillan Publishers Ltd All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir Erectile function and quality of life after interstitial radiation therapy for prostate

More information

Screening for Prostate Cancer

Screening for Prostate Cancer Screening for Prostate Cancer Review against programme appraisal criteria for the UK National Screening Committee (UK NSC) Version 1: This document summarises the work of ScHARR 1 2 and places it against

More information

Prostate Cancer Screening: Are We There Yet? March 2010 Andrew M.D. Wolf, MD University of Virginia School of Medicine

Prostate Cancer Screening: Are We There Yet? March 2010 Andrew M.D. Wolf, MD University of Virginia School of Medicine Prostate Cancer Screening: Are We There Yet? March 2010 Andrew M.D. Wolf, MD University of Virginia School of Medicine Case #1 A 55 yo white man with well-controlled hypertension presents for his annual

More information

Prostate Cancer. Treatments as unique as you are

Prostate Cancer. Treatments as unique as you are Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential

More information

Prostate Cancer 2014

Prostate Cancer 2014 Prostate Cancer 2014 Eric A. Klein, M.D. Chairman Glickman Urological and Kidney Institute Professor of Surgery Cleveland Clinic Lerner College of Medicine Incidence rates, US Men Mortality Rates, US Men

More information

Healthy People 2020 Spotlight on Health presents Promoting and Measuring Health-Related Quality of Life and Well-Being

Healthy People 2020 Spotlight on Health presents Promoting and Measuring Health-Related Quality of Life and Well-Being Healthy People 2020 Spotlight on Health presents Promoting and Measuring Health-Related Quality of Life and Well-Being Carter Blakey Deputy Director Director, Community Strategies Division Office of Disease

More information

Jennifer Fournier, RN MSN AOCN CHPN on 6/16/2012 at Oncology Nursing Society

Jennifer Fournier, RN MSN AOCN CHPN on 6/16/2012 at Oncology Nursing Society SAMPLE This Survivorship Care Plan will facilitate cancer care following active treatment. It may include important contact information, a treatment summary, recommendations for follow-up care testing,

More information

Historical Basis for Concern

Historical Basis for Concern Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical

More information